FBCIX
Price
$79.03
Change
-$0.18 (-0.23%)
Updated
Nov 19 closing price
Net Assets
119.1B
RAZAX
Price
$11.79
Change
-$0.00 (-0.00%)
Updated
Nov 19 closing price
Net Assets
576.72M
Interact to see
Advertisement

FBCIX vs RAZAX

Header iconFBCIX vs RAZAX Comparison
Open Charts FBCIX vs RAZAXBanner chart's image
American Funds Capital Income Bldr 529F2
Price$79.03
Change-$0.18 (-0.23%)
VolumeN/A
Net Assets119.1B
Russell Inv Multi-Asset Strat A
Price$11.79
Change-$0.00 (-0.00%)
VolumeN/A
Net Assets576.72M
FBCIX vs RAZAX Comparison Chart in %
View a ticker or compare two or three
Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FBCIX has more cash in the bank: 119B vs. RAZAX (577M). RAZAX (3.16) and FBCIX (3.12) have matching dividends . FBCIX was incepted earlier than RAZAX: FBCIX (5 years) vs RAZAX (8 years). RAZAX (1.32) is less costly to investors than FBCIX (0.36). RAZAX is a more actively managed with annual turnover of: 97.00 vs. FBCIX (56.00). RAZAX has a lower initial minimum investment than FBCIX: RAZAX (0) vs FBCIX (250). FBCIX annual gain was more profitable for investors over the last year : 13.32 vs. RAZAX (12.54). FBCIX return over 5 years is better than : 53.07 vs. RAZAX (25.83).
FBCIXRAZAXFBCIX / RAZAX
Total Expense Ratio0.361.1432%
Annual Report Gross Expense Ratio0.361.3227%
Fund Existence5 years8 years-
Gain YTD16.92614.047120%
Front LoadN/A6%-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets119B577M20,624%
Annual Yield % from dividends3.123.1699%
Returns for 1 year13.3212.54106%
Returns for 3 years39.2841.5894%
Returns for 5 years53.0725.83205%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPIE46.270.01
+0.02%
JPMorgan Income ETF
CPNS26.98N/A
+0.01%
Calamos Nasdaq-100 Str Alt Prt ETF-Sep
PFO9.51N/A
N/A
Flaherty & Crumrine Preferred and Income Opportunity Fund
JUNT35.48-0.08
-0.22%
AllianzIM U.S. Large Cp Buffer10 Jun ETF
HQL17.18-0.07
-0.41%
abrdn Life Sciences Investors